Comparison of rivaroxaban-based dual antithrombotic and antiplatelet therapies for symptomatic patients with lower-extremity peripheral artery disease post-revascularization: a retrospective cohort study
Ye Ji, Baoyan Wang, Guangyan Wu, Yepeng Zhang, Qing Wang, Min Zhou · 2023
Read Comparison of rivaroxaban-based dual antithrombotic and antiplatelet therapies for symptomatic patients with lower-extremity peripheral artery disease post-revascularization: a retrospective cohort study by Ye Ji, Baoyan Wang, Guangyan Wu, Yepeng Zhang, Qing Wang, Min Zhou (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10699158.txt.
Description
Ye Ji and five co-authors compare two drug plans after leg artery repair, in this 2023 study. Patients with narrowed leg arteries face heart attacks, strokes, and limb loss even after a procedure reopens the vessel. One plan uses antiplatelet drugs alone. The other adds low-dose rivaroxaban, a blood thinner, on top.
The team looked back at 1,144 patients treated at one Nanjing hospital from 2018 to 2021. The combined plan cut the pooled risk of heart attack, stroke, and heart death by about sixty percent. It also cut limb events such as urgent repeat procedures and major amputation. Major bleeding did not rise in a way that reached significance, though lesser bleeding did. The authors say high-risk Asian patients, little studied before, gain from the dual plan, and they note the study was not randomized.
Catalog record
| CREATOR | Ye Ji, Baoyan Wang, Guangyan Wu, Yepeng Zhang, Qing Wang, Min Zhou |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |